Peripheral blood stem cell source is feasible in haploidentical transplantation.
The 2-step approach allows separate control over the graft T cell and stem cell doses.
Early immune recovery was seen in both haploidentical and matched related groups.
Clinical outcomes were comparable between haploidentical and matched related groups.
Grade 2 acute graft-versus-host disease was higher in the haploidentical group.